12,372 trials
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c — -1.93; -1.06 Percentage point of HbA1c — p=<.0001
Carcinoma, Non-Small-Cell Lung
Primary: Overall Response Rate (ORR) Assessed as the Proportion of Patients With a Best Overall Response (BOR) of Either Complete Response (CR) or Partial Response (PR) — 51.6…
HIV
Primary: Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF — 0.825 proportion of participants
Exercise-related Amenorrhea
Primary: Change in Lumbar Bone Mineral Density — 0.025; 0.008; 0.012 g/cm^2 — p=0.039
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations Greater Than or Equal to (≥) the Cut-off [Follow-up Period: Persistence Analysis in…
Diabetes Mellitus, Type 2
Primary: Composite of Cardiovascular (CV) Death, MI or Stroke — 736; 818 Number of participants with event — p=0.0378
Active Systemic Lupus Erythematosus
Primary: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 — 86; 57 Participants — p=0.0013
Asthma
Primary: For FS MDPI Versus Fp MDPI: Change From Baseline in 1-Hour Postdose Percent Predicted Morning Forced Expiratory Volume in 1 Second (FEV1) at Week 12 — 16.8; 16.4; 18.2…
Hepatitis C Virus (HCV)
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 98.0 percentage of participants
Plaque Psoriasis
Primary: Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab) — 25; 88.7 percentage of participants — p=<0.001
Atopic Dermatitis
Primary: Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear…
Obsessive-Compulsive Disorder · Children · Anxiety Disorder
Primary: Children's Yale-Brown Obsessive Compulsive Scale Total Score — 20.59; 25.67 units on a scale — p=0.44
Androgenetic Alopecia
Primary: Change in Hair Diameter — 57.42; 51.58; 60.92; 51.17 micrometer
Pain · Postoperative Depression
Primary: Change in Pain Scores — 1.45; 1 score on a scale
Eosinophilic Esophagitis (EoE)
Primary: Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16) — 1; 113; 104; 100 Participants — p=<0.001